IRD
Opus Genetics, Inc.
There isn't enough reported data to score IRD yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
IRD Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Strong |
IRD's balance sheet is currently strong, but its revenue, profitability and cash flow are weak.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
IRD PE Valuation
IRD has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
IRD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Growth | |
| -- | |
| Limited | |
| Low |
Analysts expect IRD's losses to grow, with revenue growing. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
IRD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.54 | +$0.34 |
| Q2 2026 | -$1.33 | +$0.59 |
| Q1 2026 | -$1.31 | +$0.79 |
| Q4 2025 | -$0.80 | +$1.35 |
| Q3 2025 | -$1.88 | -$0.81 |
| Q2 2025 | -$1.92 | -$1.39 |
| Q1 2025 | -$2.10 | -$1.63 |
| Q4 2024 | -$2.15 | -$1.69 |
IRD is still losing money, but far less than before: $1.54 per share over the past year, against $11.55 at its worst in early 2021.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over IRD on earnings quality, reporting a profit while its opponent remains loss making.
IRD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.1M | -63% |
| Q2 2026 | $755K | -74% |
| Q1 2026 | $2.2M | -51% |
| Q4 2025 | $3.9M | -10% |
| Q3 2025 | $3.1M | -20% |
| Q2 2025 | $2.9M | +159% |
| Q1 2025 | $4.4M | +155% |
| Q4 2024 | $4.3M | +154% |
IRD's revenue has slid since its 2022 peak: $1M last quarter, down 63% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1693% | -1423 points |
| Q2 2026 | -2183% | -1874 points |
| Q1 2026 | -666% | -439 points |
| Q4 2025 | -296% | +588 points |
| Q3 2025 | -270% | -63 points |
| Q2 2025 | -309% | +440 points |
| Q1 2025 | -227% | +223 points |
| Q4 2024 | -884% | -563 points |
IRD's operating margin was −1693% last quarter, down 1423 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over IRD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over IRD on profitability, with a higher operating margin.
IRD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$12M | -$1.7M |
| Q1 2026 | -$12.7M | -$3.7M |
| Q4 2025 | -$9.8M | -$2.4M |
| Q3 2025 | -$6.2M | -$1M |
| Q2 2025 | -$10.3M | -$3M |
| Q1 2025 | -$9M | -$3.3M |
| Q4 2024 | -$7.4M | -264% |
| Q3 2024 | -$5.1M | -$2.1M |
IRD has burned cash in almost every quarter: −$41M over the past year, against −$32M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over IRD on cash generation, producing positive trailing cash flow while its opponent burns cash.
IRD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -8.6% | -9.5M shares |
| 1 year | +44% | +31.2M shares |
| 3 years | +386% | +80.9M shares |
| 5 years | +832% | +90.9M shares |
| Available history | +10187% | +101M shares |
IRD has 102M diluted shares, up 44% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over IRD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
IRD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2022 | -2.3x | Net Cash |
IRD has more cash than debt.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
IRD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.5 | Neutral |
| Stochastic | 20.4 | Neutral |
IRD's weekly RSI is 50 (neutral) and its Stochastic is 20 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
IRD PE vs Healthcare Sector
| Metric | IRD | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
IRD has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
IRD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.15 | 2.2% below |
| 20 week MA | $4.12 | 1.5% below |
| 50 week MA | $3.91 | 3.8% above |
| 100 week MA | $2.58 | 57% above |
| 200 week MA | $2.68 | 51% above |
IRD has slipped below its 8- and 20-week averages, though it's still 51% above its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over IRD on trend strength, trading above more of its moving averages.
IRD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.08 | $5.49 | -32% |
| 2021 | $5.49 | $3.81 | -31% |
| 2022 | $3.81 | $2.51 | -34% |
| 2023 | $2.51 | $3.01 | +20% |
| 2024 | $3.01 | $1.18 | -61% |
| 2025 | $1.18 | $2.02 | +71% |
| 2026 YTD | $2.02 | $4.06 | +101% |
IRD has the edge over UNH on returns for 2026, with the stronger performance.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has finished three years in a row lower, and it's up 22% so far in 2026.